NOX is massively overvalued. They have 2 university student lab experiments as their total "potential", only one of which they actually own.
They have only about 2 or 3 staff left, they have no assets, they are run out out of the CEOs house.
They will be unable to raise capital because of their reputation. Hence why the only thing propping them up is a director loan (for 15%! That's showing some faith huh!)
Ann: US FDA grants Orphan Drug Designation for CRO-67, page-35
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
